Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic mice [J]
Although several type 2 diabetes treatments are available, therapy selection involves consideration of the risks of adverse effects such as hypoglycemia (low blood sugar) or weight gain and complexity of treatment
-20C, 1 month (protect from light) Solvent & Solubility In Vitro : DMSO : 125 mg/mL ( 210.77 mM
Hypoglycemia : Blood sugar that is too low (typically below 70 mg/dL), which can be a risk if GLP-1 RAs are taken with other diabetes medications like insulin (7) Overview Baseline parameters (8) Patient parameters for use include the following: Confirmation of Type 2 diabetes Baseline HgbA1C of 8% or higher responds well to medication
